"Patient advocates are research partners. We can provide the scientific expertise; they provide the lived experience. Patients are really the ones responsible for making #ILC visible to the research community." - Dr. Mo Rimawi

Hear hear!!!
#ILCSymposium #lobmob @lobularbca.bsky.social

Dr. Karen van Baelen looked at modifiable risk factors in #ILC recurrence. Physical activity once again shown to be beneficial for #breastcancer patients! #ILCSymposium #lobmob #bcsm #exerciseismedicine

Dr. Rachel Jankowitz talks about #lobular #breastcancer in premenopausal patients. Stays say 80-85% of ILC pts are postmenopausal; 10-15% are premenopausal. BUT at UCSF, 28% of #ILC pts were premenopausal; at Penn, 35% of ILC pts were premenopausal. #ILCSymposium @lobularbca.bsky.social #lobmob

Guilford breaks down clinical management of hereditary diffuse #gastriccancer which is intense. Patients often have their stomachs removed, which comes w/ many adverse effects (& a few bennies, he noted, tongue firmly in cheek). #ILCSymposium #HDGC #lobmob #bcsm

Guilford proposes using the term hereditary diffuse gastric & #lobular #breastcancer syndrome for those w/ #CDH1 mutation since many people who survive #gastric #cancer will develop #lobularBC. #ILCSymposium @lobularbca.bsky.social @elbcc-2018.bsky.social #bcsm #lobmob

Great advocacy session this morning at the #ILCSymposium in San Francisco w/advocates from around the world. Here @clairehudson.bsky.social from @lobularbcuk.bsky.social talks about how to make it easier 4 #lobularBC patients to join #clinicaltrials. #CanSky #bcsm #lobmob

The #ILCSymposium kicks off in San Francisco w/an advocate session led by @lobularbca.bsky.social advocates and Dr. Rita Mukhtar. #CanSky #bcsm #lobmob